First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640 - European Medical Journal

Continue

First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

Oncology
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given